Novoviah Pharmaceuticals, in collaboration with the Walter and Eliza Hall Institute, has developed a novel blood test measuring gluten-specific T cell reactivity via IL-2 release, demonstrating 90% sensitivity and 95% specificity in detecting celiac disease. Unlike traditional diagnostic methods requiring gluten consumption and invasive biopsies, this assay detects disease presence even in patients on gluten-free diets, potentially streamlining celiac disease diagnosis and monitoring in clinical practice. Results were published in Gastroenterology.